The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Source: Pixabay.com

The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

A drug to treat prostate cancer has been approved by the US Food and Drug Administration. The drug, Xtandi ® (enzalutamide), had previously been approved for castration-resistant prostate cancer (CRPC)…

Continue Reading The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
There’s More Than One Way to Treat Cancer
Source: Pixabay.com

There’s More Than One Way to Treat Cancer

In an Article from AsiaOne.com, we meet John Ryan, retired nuclear reactor specialist who worked for the military when he was diagnosed with lung cancer. Now in remission he might…

Continue Reading There’s More Than One Way to Treat Cancer
Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research
allinonemovie / Pixabay

Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research

A recent study, published here in the journal Nature Medicine and used as the source for this article, has found that certain kinds of cells may be useful for predicting…

Continue Reading Natural Killer Cells May Be Useful For Predicting How Patients Respond to Certain Immunotherapies, According to Recent Research
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma
Source: Pixabay

The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma

The U.S. Food and Drug Administration (FDA) has approved the medicine Keytruda for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, that have relapsed…

Continue Reading The FDA has approved Keytruda For the Treatment of Refractory Primary Mediastinal Large B-cell Lymphoma
The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
Source: Pixabay

The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma

Pfizer has announced that the medicine Xalkori (crizotinib) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for two potential treatment uses. The full article can be…

Continue Reading The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
Source: Pixabay

$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients

The Melanoma Research Alliance (MRA) and The American Cancer Society (ACS) have announced the first recipients of their new research grants, reports PRNewswire. The grants have been set up as…

Continue Reading $2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
Source: Pixabay

A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia

A phase 3 Murano clinical trial has shown that combining the drugs Venclexta (venetoclax) and Rituxan (rituximab) could be an effective treatment for chronic lymphocytic leukaemia, reports Cancer Updates, Research,…

Continue Reading A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.
Source: Pixabay

A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.

The US Food and Drug Administration (FDA) has just awarded Breakthrough Therapy Designation to a drug (OMS721) being developed to treat thrombotic microangiopathy that has developed as a result of haematopoietic stem…

Continue Reading A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.
Teens and Young Adults are Less Likely to Stick to Follow-up Guidelines After Cancer Treatment
source: pixabay.com

Teens and Young Adults are Less Likely to Stick to Follow-up Guidelines After Cancer Treatment

According to a story from The European Society For Medical Oncology, a recent study shows that young adults and teenagers are less likely to adhere to follow-up guidelines following treatment…

Continue Reading Teens and Young Adults are Less Likely to Stick to Follow-up Guidelines After Cancer Treatment
New Study Explains Why Elephants Don’t Get Cancer and Could Lead to New Treatments For Humans
Source: Pixabay

New Study Explains Why Elephants Don’t Get Cancer and Could Lead to New Treatments For Humans

A team lead by geneticist Christopher Gregg from the University of Utah conducted a study on elephant genes that discovered why elephants don't get cancer, reported by News 4 Tucson.…

Continue Reading New Study Explains Why Elephants Don’t Get Cancer and Could Lead to New Treatments For Humans